NCT01667822

Brief Summary

Background: Studies show that about 1 out of 3 patients in Primary Care suffer primarily from mental health disorders, such as anxiety disorders and depression. Cognitive behavior therapy (CBT) has been shown to be an effective treatment of these disorders. Despite the strong evidence for CBT there is a lack of evidence-based psychological treatment in primary care. For various reasons, the progress of research has not affected clinical practice. For successful implementation of CBT in primary care cost-effective therapies, access to therapists with proper training and supervision, evidence-based manuals and management that support the implementation is needed. Aim: The aim of this trial is to evaluate a stepped care model with CBT in primary care. All patients are first treated with self-help CBT (N = 400). Patients that do not improve after treatment (9 weeks) are randomized to individual CBT or continued self-help treatment. Based on published studies 2/3 is expected to be improved after self-help and therefore do not undergo randomization. 1/3 (n = 133) who didn´t respond to treatment is randomized to individual CBT (N = 67) or continued self-help treatment (N = 67).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
396

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Aug 2012

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2012

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

August 10, 2012

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 17, 2012

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

October 18, 2016

Status Verified

October 1, 2016

Enrollment Period

3.3 years

First QC Date

August 10, 2012

Last Update Submit

October 14, 2016

Conditions

Outcome Measures

Primary Outcomes (4)

  • Absolute improvement in disorder specific symptoms defined as closer to healthy than to clinical population or 2 standard deviations from clinical population

    Absolute improvement, i.e., symptom level below pre-established cut-offs at 9 weeks, 20 weeks, 26 week follow-up, and 52 week follow-up compared to baseline.

    9 weeks

  • Absolute improvement in disorder specific symptoms defined as closer to healthy than to clinical population or 2 standard deviations from clinical population

    Absolute improvement in disorder specific symptoms defined as closer to healthy than to clinical population or 2 standard deviations from clinical population

    20 weeks

  • Absolute improvement in disorder specific symptoms defined as closer to healthy than to clinical population or 2 standard deviations from clinical population

    Absolute improvement in disorder specific symptoms defined as closer to healthy than to clinical population or 2 standard deviations from clinical population

    26 weeks

  • Absolute improvement in disorder specific symptoms defined as closer to healthy than to clinical population or 2 standard deviations from clinical population

    Absolute improvement in disorder specific symptoms defined as closer to healthy than to clinical population or 2 standard deviations from clinical population

    52 weeks

Secondary Outcomes (14)

  • Montgomery-Åsberg Depression Rating Scale-Self-report (MADRS-S)

    Baseline, post-treatment (20 weeks), 26 week follow-up, 52 week follow-up

  • Work ability index (WAI)

    Baseline, post-treatment (20 weeks), 26 week follow-up, 52 week follow-up

  • Insomnia Severity Index (ISI)

    Baseline, post-treatment (20 weeks), 26 week follow-up, 52 week follow-up

  • Health Anxiety Inventory (HAI)

    Baseline, post-treatment (20 weeks), 26 week follow-up, 52 week follow-up

  • Perceived Stress Scale (PSS)

    Baseline, post-treatment (20 weeks), 26 week follow-up, 52 week follow-up

  • +9 more secondary outcomes

Other Outcomes (1)

  • Inflammatory cytokines

    Baseline, post-treatment (20 weeks)

Study Arms (2)

Continued guided self help CBT

ACTIVE COMPARATOR

Continued guided self help CBT. Participants will receive CBT through self-help books with minimal therapist contact (3 sessions in total).

Behavioral: Continued self help CBT

CBT individual therapy

EXPERIMENTAL

After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.

Behavioral: Individual CBT

Interventions

After the initial Guided self help, patients in this arm continue the same self help program with 1 additional guiding session.

Continued guided self help CBT
Individual CBTBEHAVIORAL

After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.

CBT individual therapy

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Have an anxiety disorder diagnosis (obsessive compulsive disorder, social phobia, panic disorder, generalized anxiety disorder), or/and major depression, or/and maladaptive stress reaction, or/and primary insomnia Clinician severity rating scale 2-6

You may not qualify if:

  • A higher score than 6 on the Clinician severity rating scale

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Karolinska Institutet and Gustavsberg primary care center

Stockholm, Stockholm County, 13440, Sweden

Location

MeSH Terms

Conditions

Anxiety DisordersDepressive Disorder, MajorStress Disorders, TraumaticSleep Initiation and Maintenance Disorders

Condition Hierarchy (Ancestors)

Mental DisordersDepressive DisorderMood DisordersTrauma and Stressor Related DisordersSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

August 10, 2012

First Posted

August 17, 2012

Study Start

August 1, 2012

Primary Completion

December 1, 2015

Study Completion

December 1, 2015

Last Updated

October 18, 2016

Record last verified: 2016-10

Locations